Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals has reported its financial results for the year ended 31 December 2025, showing revenue from contracts with customers rising 56% to US$803.8 million compared with 2024. Despite this strong top-line growth, the company swung to a net loss after tax of US$7.1 million, versus a prior-year profit of US$33.7 million, and total comprehensive income also moved into negative territory.
The Board confirmed that no dividend was proposed or paid for 2025, indicating an ongoing focus on reinvestment rather than capital returns, which may affect income-focused shareholders. Telix also announced its 2026 Annual General Meeting will be held on 21 May in Melbourne, with a 9 April deadline for director nominations, setting the timetable for upcoming governance and strategic discussions with investors.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercialising radiopharmaceutical and molecularly targeted oncology products. Listed on both the ASX and Nasdaq, the company operates globally from bases in Australia and the U.S., targeting cancer diagnosis and treatment markets with specialised nuclear medicine therapeutics and diagnostics.
Average Trading Volume: 2,324,604
Technical Sentiment Signal: Sell
Current Market Cap: A$2.99B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.